Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Innova Captab's Revenue for the
three
months ended in Jun. 2026 was ₹4,709 Mil. Innova Captab's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹4,373 Mil.
Hence, Innova Captab's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.08.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Innova Captab Receivables Turnover Related Terms
Innova Captab Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Innova Captab's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INNOVACAP vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innova Captab Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Innova Captab's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Innova Captab's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innova Captab (NSE:INNOVACAP) has a Receivables Turnover of 1.08 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Innova Captab and its competitors. According to the industry distribution chart, Innova Captab ranks #554 out of 947 companies in the Drug Manufacturers industry, placing it in the top 58.5%.
Is Innova Captab's Receivables Turnover too high?
Innova Captab's current Receivables Turnover is 1.08. The Drug Manufacturers industry median Receivables Turnover is 5.08. Innova Captab's value of 1.08 is 78.7% below this industry median. Based on the distribution chart, Innova Captab ranks #554 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Innova Captab has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Innova Captab ranks #554 out of 947 companies for Receivables Turnover. This places Innova Captab in the lower half of its industry. The industry median Receivables Turnover is 5.08. Innova Captab's value of 1.08 is 78.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innova Captab's current Receivables Turnover of 1.08 is 78.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Innova Captab and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innova Captab's current Receivables Turnover is 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Based on GuruFocus' analysis, Innova Captab (NSE:INNOVACAP) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,067.35, compared to a current price of ₹1,021.55 — trading 4.3% below its estimated fair value. The current Receivables Turnover is 1.08 and 78.7% below the Drug Manufacturers industry median of 5.08. Innova Captab's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Innova Captab (NSE:INNOVACAP), the current Receivables Turnover is 1.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innova Captab (NSE:INNOVACAP) Overvalued in 2026?
Based on GuruFocus' analysis, Innova Captab stock appears to be undervalued.
The current stock price of ₹1,021.55 is trading 4.3% below its estimated GF Value™ of ₹1,067.35.
GuruFocus considers Innova Captab to be Fairly Valued.
Key valuation signals for NSE:INNOVACAP:
Receivables Turnover: 1.08
GF Value™: ₹1,067.35 vs. price of ₹1,021.55 (4.3% below fair value)
Industry Position: 78.7% below the Drug Manufacturers median (#554 of 947)
No single metric tells the full story. See the NSE:INNOVACAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
68GF Score
Get the complete analysis for NSE:INNOVACAP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INNOVACAP has been successfully added to your 
